Alexion Pharmaceuticals (NASDAQ: ALXN) is one of 45 public companies in the “Biopharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Alexion Pharmaceuticals to similar companies based on the strength of its valuation, risk, analyst recommendations, profitability, dividends, earnings and institutional ownership.

Profitability

This table compares Alexion Pharmaceuticals and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Alexion Pharmaceuticals 15.31% 12.47% 8.15%
Alexion Pharmaceuticals Competitors -13,072.07% 230.44% -22.70%

Earnings & Valuation

This table compares Alexion Pharmaceuticals and its competitors gross revenue, earnings per share and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Alexion Pharmaceuticals $3.41 billion $1.34 billion 61.83
Alexion Pharmaceuticals Competitors $579.33 million $241.78 million -6.39

Alexion Pharmaceuticals has higher revenue and earnings than its competitors. Alexion Pharmaceuticals is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Alexion Pharmaceuticals and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Alexion Pharmaceuticals 0 5 17 1 2.83
Alexion Pharmaceuticals Competitors 191 912 1685 67 2.57

Alexion Pharmaceuticals presently has a consensus price target of $158.41, suggesting a potential upside of 10.92%. As a group, “Biopharmaceuticals” companies have a potential upside of 5.97%. Given Alexion Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts plainly believe Alexion Pharmaceuticals is more favorable than its competitors.

Insider and Institutional Ownership

94.2% of Alexion Pharmaceuticals shares are owned by institutional investors. Comparatively, 45.3% of shares of all “Biopharmaceuticals” companies are owned by institutional investors. 4.4% of Alexion Pharmaceuticals shares are owned by insiders. Comparatively, 13.9% of shares of all “Biopharmaceuticals” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Alexion Pharmaceuticals has a beta of 1.4, indicating that its share price is 40% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals’ competitors have a beta of 1.24, indicating that their average share price is 24% more volatile than the S&P 500.

Summary

Alexion Pharmaceuticals beats its competitors on 11 of the 13 factors compared.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous). Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS). PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system. Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP). Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D). It is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.